S-1 · resale registration
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
DAVI$1.42-5.03%
Davion Healthcare PLC
Sector: Surgical & Medical Instruments & ApparatusIndustry: Medical - DevicesCountry: IEExchange: Nasdaq
Mkt Cap:$35.38M
Float & O/S:
Inst Own:
DilutionScan read 18 of DAVION HEALTHCARE PLC's SEC filings and found 1 warrant series, 1 convertible, 1 S-1 registration and 2 completed offerings on file for DAVI. The latest dilution event on file is an offering on Mar 10, 2026. Analysis updated Oct 28, 2026.
Signal8 Summary
DAVI
Newly listed micro-cap, dilutive deal-funding
- Business
- MixedNo revenue/income data; $25M deal funded via cash, new shares
- Stock risk
- High$101.8M cap, 76% below 52-week high, 0% institutional ownership
Snapshot
Davion is a newly Nasdaq-listed healthcare device company that just overhauled its leadership and, on Oct 26, 2026, bought wound-care and diagnostic test IP for $25 million, paid partly in cash and partly in new shares.
What's Happening Right Now
- : On Oct 26, 2026, Davion completed its first acquisition since listing on Nasdaq, buying the WoundSkan wound-monitoring dressing and Spektra lateral flow test IP for $25 million ($2.5M cash plus 1,730,770 new shares priced at $13), and launched a £30 million secured bond to fund further acquisitions.
- : Ahead of its Oct 22, 2026 Nasdaq debut under ticker DAVI, Davion installed Glenn Williams as CEO and Jeremy North as COO, moved prior CEO Jack Kaye to Executive Chairman, and created a new Operational Directorate to run commercialisation and acquisitions.
Raise routes on file: effective S-1 · latest dilution event 238 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Mar 10, 2026 · Offering
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Effective
Warrant
Issued 2026
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your DAVI trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
